ketoconazole has been researched along with propranolol in 41 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.44) | 18.7374 |
| 1990's | 1 (2.44) | 18.2507 |
| 2000's | 13 (31.71) | 29.6817 |
| 2010's | 24 (58.54) | 24.3611 |
| 2020's | 2 (4.88) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Buchynskyy, A; Buckner, FS; Gelb, MH; Gillespie, JR; Herbst, ZM; Ranade, RM | 1 |
| Bloomer, WD; Papadopoulou, MV; Rosenzweig, HS | 1 |
| Barouch-Bentov, R; Brannan, JM; De Jonghe, S; Dye, JM; Einav, S; Herdewijn, P; O'Brien, CM; Prugar, LI; Pu, SY; Rozenski, J; Schor, S; Wouters, R | 1 |
| Cini, E; De Santis, R; Giannini, G; Manera, F; Manetti, F; Milazzo, FM; Pace, S; Petricci, E; Stasi, MA; Tallarico, C; Vesci, L | 1 |
| Bartel, K; Bracher, F; Christianson, DW; Herp, D; Jung, M; Marek, M; Müller, M; Ong, N; Porter, NJ; Robaa, D; Romier, C; Schmidtkunz, K; Senger, J; Shaik, TB; Sippl, W; Vögerl, K | 1 |
| Consoli, V; D'Agata, V; D'Amico, AG; Fallica, AN; Floresta, G; Intagliata, S; Pittalà, V; Rescifina, A; Romeo, G; Salerno, L; Sorrenti, V; Vanella, L | 1 |
| Bandopadhyay, P; Das, N; Dastidar, UG; Ganguly, D; Pal, S; Rahaman, O; Roy, S; Sinha, BP; Talukdar, A | 1 |
| Cvetkovic, M; Kim, RB; Leake, B; Nadeau, J; Roden, MM; Walubo, A; Wilkinson, GR | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Pajeva, IK; Wiese, M | 1 |
| Bacsó, Z; Cianfriglia, M; Fenyvesi, F; Goda, K; Kappelmayer, J; Lustyik, G; Nagy, H; Szabó, G; Szilasi, M | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Artursson, P; Bergström, CA; Draheim, R; Holmén, AG; Wassvik, CM | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, L; Conda-Sheridan, M; Cushman, M; Kondratyuk, TP; Morrell, A; Park, EJ; Pezzuto, JM; Reddy, PV; van Breemen, RB | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Beeley, L | 1 |
| Azzarano, LM; Kehler, JR; McSurdy-Freed, JE; Morgan, JA; Proksch, JW; Smith, BR; Stelman, GJ; Ward, KW; Zeigler, KS | 1 |
| Alnouti, Y; Bi, H; Gusev, AI; Leverence, R; Li, M | 1 |
| Alnouti, Y; Bi, H; Gusev, AI; Kavetskaia, O; Srinivasan, K; Waddell, D | 1 |
| Hao, A; Li, J; Wei, Y; Zhao, M; Zhu, C | 1 |
| Foroumadi, A; Hosseini, NM; Massarrat, S; Pedramnia, S; Saniee, P; Siavoshi, F; Tavakolian, A | 1 |
| Finnerty, CC; Herndon, DN; Radhakrishnan, RS; Rojas, Y | 1 |
| Scriba, GK | 1 |
4 review(s) available for ketoconazole and propranolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug-induced sexual dysfunction and infertility.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzothiadiazines; Child; Cimetidine; Clonidine; Cytotoxins; Diuretics; Ejaculation; Erectile Dysfunction; Ethanol; Female; Humans; Infertility; Infertility, Female; Infertility, Male; Ketoconazole; Libido; Male; Methyldopa; Middle Aged; Narcotics; Orgasm; Parasympatholytics; Penis; Phenothiazines; Propranolol; Sexual Dysfunction, Physiological; Sodium Chloride Symporter Inhibitors; Sulfasalazine | 1984 |
Burns: an update on current pharmacotherapy.
Topics: Adrenergic beta-Antagonists; Anabolic Agents; Animals; Burns; Growth Hormone; Humans; Hypoglycemic Agents; Ketoconazole; Oxandrolone; Propranolol; Testosterone | 2012 |
Differentiation of enantiomers by capillary electrophoresis.
Topics: Amino Acids; Chromatography, Micellar Electrokinetic Capillary; Crown Ethers; Cyclodextrins; Dipeptides; Electrophoresis, Capillary; Glycopeptides; Ketoconazole; Kinetics; Propranolol; Stereoisomerism; Surface-Active Agents; Thermodynamics | 2013 |
37 other study(ies) available for ketoconazole and propranolol
| Article | Year |
|---|---|
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
1-Benzyl-3-aryl-2-thiohydantoin Derivatives as New Anti-
Topics: | 2017 |
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
Topics: Animals; Antitubercular Agents; Cell Line; Chlorocebus aethiops; Dose-Response Relationship, Drug; Humans; Imidazoles; Macrophages; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitro Compounds; Structure-Activity Relationship; Triazoles | 2017 |
Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.
Topics: Antiviral Agents; Cell Line; Humans; Intracellular Signaling Peptides and Proteins; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Structure-Activity Relationship; Thiazoles | 2018 |
Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Guanidine; Hedgehog Proteins; Humans; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; NIH 3T3 Cells; Structure-Activity Relationship; Thiourea | 2018 |
Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
Topics: Acetylation; Animals; Catalytic Domain; Cells, Cultured; Crystallography, X-Ray; Histone Deacetylase 6; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; In Vitro Techniques; Microsomes, Liver; Molecular Docking Simulation; Molecular Structure; Phenothiazines; Structure-Activity Relationship; Zebrafish | 2019 |
Discovery of Novel Acetamide-Based Heme Oxygenase-1 Inhibitors with Potent
Topics: Acetamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Humans; Male; Molecular Docking Simulation; Molecular Structure; Protein Binding; Rats, Sprague-Dawley; Structure-Activity Relationship | 2021 |
Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.
Topics: Imidazoles; Ligands; Pyridines; Toll-Like Receptor 7; Toll-Like Receptor 9 | 2022 |
Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity.
Topics: Bile Acids and Salts; Biological Transport, Active; Carrier Proteins; Cells, Cultured; HeLa Cells; Humans; Kinetics; Liver; Nicotine; Organic Anion Transporters, Sodium-Dependent; Plasmids; RNA, Messenger; Salicylates; Symporters; Vaccinia virus; Valproic Acid | 1999 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).
Topics: Adenosine Triphosphatases; Algorithms; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Binding, Competitive; Caco-2 Cells; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluoresceins; Humans; Ligands; Models, Molecular; Molecular Structure; Quantitative Structure-Activity Relationship; Radioligand Assay; Rhodamine 123; Stereoisomerism; Verapamil; Vinblastine | 2002 |
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Molecular characteristics for solid-state limited solubility.
Topics: Chemical Phenomena; Chemistry, Physical; Molecular Structure; Multivariate Analysis; Pharmaceutical Preparations; Regression Analysis; Solubility | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventi
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Cell Line, Tumor; Chemistry Techniques, Synthetic; Drug Discovery; Drug Stability; Female; Humans; Indenes; Isoquinolines; Ligands; Microsomes, Liver; Rats; Response Elements; Retinoid X Receptors; Transcription, Genetic | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.
Topics: Absorption; Administration, Oral; Animals; Area Under Curve; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Erythromycin; Half-Life; Injections, Intravenous; Ketoconazole; Liver; Macaca fascicularis; Male; Oxidoreductases, N-Demethylating; Propranolol; Time Factors; Xenobiotics | 2004 |
Increase of the LC-MS/MS sensitivity and detection limits using on-line sample preparation with large volume plasma injection.
Topics: Animals; Calibration; Chromatography, Liquid; Ketoconazole; Propranolol; Rats; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2005 |
Development and application of a new on-line SPE system combined with LC-MS/MS detection for high throughput direct analysis of pharmaceutical compounds in plasma.
Topics: Chemical Fractionation; Chromatography, High Pressure Liquid; Diclofenac; Ibuprofen; Ketoconazole; Mass Spectrometry; Online Systems; Pharmaceutical Preparations; Propranolol; Reproducibility of Results | 2005 |
2-O-(2-hydroxybutyl)-beta-cyclodextrin as a chiral selector for the capillary electrophoretic separation of chiral drugs.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Antifungal Agents; beta-Cyclodextrins; Chlorpheniramine; Electrophoresis, Capillary; Epinephrine; Histamine H1 Antagonists; Hydrogen-Ion Concentration; Ketoconazole; Molecular Conformation; Molecular Structure; Promethazine; Propranolol; Solanaceous Alkaloids | 2005 |
Comparison of the effect of non-antifungal and antifungal agents on Candida isolates from the gastrointestinal tract.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amphotericin B; Antifungal Agents; Antipsychotic Agents; Candida; Candida tropicalis; Colony Count, Microbial; Drug Resistance, Microbial; Gastrointestinal Tract; Humans; Ketoconazole; Lansoprazole; Propranolol; Trifluoperazine | 2012 |